We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Beam Technology Enables Less Harmful, More Accurate, and Cost-Effective Radiotherapy

By HospiMedica International staff writers
Posted on 21 Apr 2014
Newly developed technology will enable more effective, less harmful, and drastically less costly radiotherapy and radiosurgery treatment using low-energy X-ray tubes instead of high-energy sources typically used today. More...


Convergent R.N.R., Ltd. (CRnR; Tirat Carmel, Israel) has completed a very effective and promising proof-of-concept session of the Mercy Beam technology.

The Mercy Beam introduces an advanced lens that gathers most of the X-rays emanating divergently out of any traditional X-ray tube (currently used for X-ray imaging) and converges it towards the tumor site. The lens simultaneously removes low-energy photons that would be absorbed by the patient’s skin. The convergence increases the therapeutic dose delivered at the tumor target, while the organs in the vicinity of the tumor receive a very low dose or no dose at all. The converging technology enables the use of photon-energy X-rays 100 times lower than those used by current systems that are based on linear accelerators (LINACs). This technology, because of its low energy requirement, enables a small, light and inexpensive solution in which the cancer is treated accurately with a concentrated radiation at a fraction of the cost of all other methods.

“Today’s radiation treatment and surgery uses very high energy X-ray radiation that not only penetrates the body to reach the tumor, but also scatters towards the surrounding environment including healthy tissue, causing unwanted damage,” said Zeev Harel, CEO of CRnR. “To deal with such high energy X-rays, the protocol requires the machine installation inside a room of several feet of concrete walls, and heavy lead doors, which make those solutions even more expensive. Mercy Beam would revolutionize cancer treatment as we know it today, allowing many patients to receive a merciful, efficient and affordable treatment. The use of low energy X-rays will enable operating the system in standard X-ray rooms [no need for ‘special bunkers’] and in the future even in vans/lorries/trailers that may travel to remote areas. The technology is targeted for treating many types of cancerous tumors with an emphasis on treating of small children.”

Convergent R.N.R. (CRnR) is a medical start-up company developing a new X-ray focusing technology called MercyBeam to perform cancer radiotherapy and radiosurgery. CRnR developed and patented the said break-through technology utilizing a standard imaging X-ray source to form a converging beam into a volume of treatment instead of the conventional diverging or collimated technologies existing today.

Related Links:

Convergent R.N.R.
Mercy Beam



Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Fetal Monitor
BT-380
Desk Aneroid Sphyg
Diagnostix 750D+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The investigational niia signature wearable patch combines continuous glucose monitoring, insulin delivery, and automated glucose control in a single system. (photo courtesy of PharmaSens)

Wearable Patch Prototype Advances Toward Integrated Automated Insulin Delivery

Diabetes management requires individualized care, reliable glucose and ketone monitoring, and timely intervention. For automated insulin delivery, a key challenge is maintaining accurate glucose measurements... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: The proposed acquisition would add NeoCast, an investigational next-generation liquid embolic technology for chronic subdural hematoma (cSDH), to Terumo Neuro’s neurovascular portfolio. (Photo courtesy of Arsenal Medical)

Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma

Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.